{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:19:31Z","timestamp":1781540371188,"version":"3.54.5"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA208610"],"award-info":[{"award-number":["R21 CA208610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3 ES029073"],"award-info":[{"award-number":["UG3 ES029073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA240301"],"award-info":[{"award-number":["CA240301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008522","name":"University of Illinois at Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008522","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-grade serous ovarian cancer (HGSOC) is thought to progress from a series of precursor lesions in the fallopian tube epithelium (FTE). One of the preneoplastic lesions found in the FTE is called a secretory cell outgrowth (SCOUT), which is partially defined by a loss of paired box 2 (PAX2). In the present study, we developed PAX2-deficient murine cell lines in order to model a SCOUT and to explore the role of PAX2 loss in the etiology of HGSOC. Loss of PAX2 alone in the murine oviductal epithelium (MOE) did not induce changes in proliferation, migration and survival in hypoxia or contribute to resistance to first line therapies, such as cisplatin or paclitaxel. RNA sequencing of MOE PAX2shRNA cells revealed significant alterations in the transcriptome. Silencing of PAX2 in MOE cells produced a messenger RNA expression pattern that recapitulated several aspects of the transcriptome of previously characterized human SCOUTs. RNA-seq analysis and subsequent qPCR validation of this SCOUT model revealed an enrichment of genes involved in estrogen signaling and an increase in expression of estrogen receptor \u03b1. MOE PAX2shRNA cells had higher estrogen signaling activity and higher expression of putative estrogen responsive genes both in the presence and absence of exogenous estrogen. In summary, loss of PAX2 in MOE cells is sufficient to transcriptionally recapitulate a human SCOUT, and this model revealed an enrichment of estrogen signaling as a possible route for tumor progression of precursor lesions in the fallopian tube.<\/jats:p>","DOI":"10.1093\/carcin\/bgz127","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:09:22Z","timestamp":1562094562000},"page":"646-655","source":"Crossref","is-referenced-by-count":14,"title":["Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling"],"prefix":"10.1093","volume":"41","author":[{"given":"Jose A","family":"Colina","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Varughese","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Karthikeyan","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Salvi","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimple A","family":"Modi","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna E","family":"Burdette","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"2020071008541975400_CIT0001","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2020071008541975400_CIT0002","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/modpathol.3800306","article-title":"Origins and molecular pathology of ovarian cancer","volume":"18","author":"Bell","year":"2005","journal-title":"Mod. Pathol."},{"key":"2020071008541975400_CIT0003","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/cancers10080262","article-title":"UnPAXing the divergent roles of PAX2 and PAX8 in high-grade serous ovarian cancer","volume":"10","author":"Hardy","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2020071008541975400_CIT0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2015.10.022","article-title":"Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide","volume":"141","author":"Singh","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"2020071008541975400_CIT0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.5145","article-title":"Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas","volume":"246","author":"Soong","year":"2018","journal-title":"J. Pathol."},{"key":"2020071008541975400_CIT0006","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"2020071008541975400_CIT0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J. Pathol."},{"key":"2020071008541975400_CIT0008","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2018.11.033","article-title":"The fallopian tube, \u201cprecursor escape\u201d and narrowing the knowledge gap to the origins of high-grade serous carcinoma","volume":"152","author":"Soong","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"2020071008541975400_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/path.2739","article-title":"Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube","volume":"222","author":"Chen","year":"2010","journal-title":"J. Pathol."},{"key":"2020071008541975400_CIT0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/modpathol.2011.175","article-title":"PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer","volume":"25","author":"Quick","year":"2012","journal-title":"Mod. Pathol."},{"key":"2020071008541975400_CIT0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/path.4417","article-title":"The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium","volume":"234","author":"Ning","year":"2014","journal-title":"J. Pathol."},{"key":"2020071008541975400_CIT0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3892\/br.2017.955","article-title":"The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer","volume":"7","author":"Kobayashi","year":"2017","journal-title":"Biomed. Rep."},{"key":"2020071008541975400_CIT0013","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/modpathol.2017.53","article-title":"LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions","volume":"30","author":"Schmoeckel","year":"2017","journal-title":"Mod. Pathol."},{"key":"2020071008541975400_CIT0014","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.3390\/ijms14036090","article-title":"PAX2 expression in ovarian cancer","volume":"14","author":"Song","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"2020071008541975400_CIT0015","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/modpathol.2010.119","article-title":"High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression","volume":"23","author":"Roh","year":"2010","journal-title":"Mod. Pathol."},{"key":"2020071008541975400_CIT0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrc1778","article-title":"A PANorama of PAX genes in cancer and development","volume":"6","author":"Robson","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2020071008541975400_CIT0017","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1242\/dev.109.4.787","article-title":"Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system","volume":"109","author":"Dressler","year":"1990","journal-title":"Development"},{"key":"2020071008541975400_CIT0018","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1940-6207.CAPR-15-0121-T","article-title":"Divergent roles of PAX2 in the etiology and progression of ovarian cancer","volume":"8","author":"Al-Hujaily","year":"2015","journal-title":"Cancer Prev. Res. (Phila)."},{"key":"2020071008541975400_CIT0019","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41388-017-0097-8","article-title":"PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation","volume":"37","author":"Russo","year":"2018","journal-title":"Oncogene"},{"key":"2020071008541975400_CIT0020","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/onc.2016.455","article-title":"PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer","volume":"36","author":"Modi","year":"2017","journal-title":"Oncogene"},{"key":"2020071008541975400_CIT0021","doi-asserted-by":"crossref","first-page":"76881","DOI":"10.18632\/oncotarget.20173","article-title":"PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state","volume":"8","author":"Alwosaibai","year":"2017","journal-title":"Oncotarget"},{"key":"2020071008541975400_CIT0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1476-4598-10-148","article-title":"PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype","volume":"10","author":"Beauchemin","year":"2011","journal-title":"Mol. Cancer"},{"key":"2020071008541975400_CIT0023","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3892\/mco.2016.935","article-title":"Paired box gene 2 is associated with estrogen receptor \u03b1 in ovarian serous tumors: potential theory basis for targeted therapy","volume":"5","author":"Wang","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"2020071008541975400_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(96)00216-8","article-title":"Estrogen action in human ovarian cancer","volume":"25","author":"Clinton","year":"1997","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2020071008541975400_CIT0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1290\/1071-2690(2000)036<0657:ESOOSE>2.0.CO;2","article-title":"Estrogen stimulation of ovarian surface epithelial cell proliferation","volume":"36","author":"Bai","year":"2000","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"2020071008541975400_CIT0026","first-page":"1009","article-title":"Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro","volume":"73","author":"Nash","year":"1989","journal-title":"Obstet. Gynecol."},{"key":"2020071008541975400_CIT0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/GME.0000000000000550","article-title":"Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Menopause"},{"key":"2020071008541975400_CIT0028","first-page":"6768","article-title":"Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells","volume":"61","author":"Syed","year":"2001","journal-title":"Cancer Res."},{"key":"2020071008541975400_CIT0029","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.285.11.1460","article-title":"Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women","volume":"285","author":"Rodriguez","year":"2001","journal-title":"JAMA"},{"key":"2020071008541975400_CIT0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.288.3.334","article-title":"Menopausal hormone replacement therapy and risk of ovarian cancer","volume":"288","author":"James","year":"2002","journal-title":"JAMA"},{"key":"2020071008541975400_CIT0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7827-1-73","article-title":"Estrogen, progesterone and epithelial ovarian cancer","volume":"1","author":"Ho","year":"2003","journal-title":"Reprod. Biol. Endocrinol."},{"key":"2020071008541975400_CIT0032","doi-asserted-by":"crossref","first-page":"e65067","DOI":"10.1371\/journal.pone.0065067","article-title":"Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas","volume":"8","author":"Quartuccio","year":"2013","journal-title":"PLoS One"},{"key":"2020071008541975400_CIT0033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/carcin\/bgy170","article-title":"Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer","volume":"40","author":"Dean","year":"2019","journal-title":"Carcinogenesis"},{"key":"2020071008541975400_CIT0034","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13059-016-1012-2","article-title":"Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR","volume":"17","author":"Haeussler","year":"2016","journal-title":"Genome Biol."},{"key":"2020071008541975400_CIT0035","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1101\/gad.10.8.1008","article-title":"Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes","volume":"10","author":"Tucker","year":"1996","journal-title":"Genes Dev."},{"key":"2020071008541975400_CIT0036","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"2020071008541975400_CIT0037","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"2020071008541975400_CIT0038","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12672-018-0333-x","article-title":"The flavonoid apigenin is a progesterone receptor modulator with in vivo activity in the uterus","volume":"9","author":"Dean","year":"2018","journal-title":"Horm. Cancer"},{"key":"2020071008541975400_CIT0039","doi-asserted-by":"crossref","first-page":"22650","DOI":"10.18632\/oncotarget.7998","article-title":"Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer","volume":"7","author":"Gomez-Roman","year":"2016","journal-title":"Oncotarget"},{"key":"2020071008541975400_CIT0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13048-016-0213-3","article-title":"Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators","volume":"9","author":"Moyle-Heyrman","year":"2016","journal-title":"J. Ovarian Res."},{"key":"2020071008541975400_CIT0041","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/gb-2004-5-9-r66","article-title":"Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells","volume":"5","author":"Lin","year":"2004","journal-title":"Genome Biol."},{"key":"2020071008541975400_CIT0042","doi-asserted-by":"crossref","first-page":"15939","DOI":"10.1073\/pnas.0604041103","article-title":"Differential sensitivities of transcription factor target genes underlie cell type-specific gene expression profiles","volume":"103","author":"Johnson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2020071008541975400_CIT0043","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1073\/pnas.0506164102","article-title":"Chromatin domain activation via GATA-1 utilization of a small subset of dispersed GATA motifs within a broad chromosomal region","volume":"102","author":"Im","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2020071008541975400_CIT0044","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: an Endocrine Society scientific statement","volume":"95","author":"Santen","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2020071008541975400_CIT0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.celrep.2013.01.010","article-title":"Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor","volume":"3","author":"Mohammed","year":"2013","journal-title":"Cell Rep."},{"key":"2020071008541975400_CIT0046","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fcell.2014.00034","article-title":"Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development","volume":"2","author":"Manavathi","year":"2014","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgz127\/28980284\/bgz127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/41\/5\/646\/33481272\/bgz127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/41\/5\/646\/33481272\/bgz127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T19:44:36Z","timestamp":1663875876000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/41\/5\/646\/5528129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,7,4]]},"published-print":{"date-parts":[[2020,7,10]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgz127","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,7,4]]}}}